Get the Stockscreener App
3.40
5.29%
-0.19
After Hours:
3.47
0.07
+2.06%
Larimar Therapeutics Inc stock is traded at $3.40, with a volume of 923.64K.
It is down -5.29% in the last 24 hours and down -5.03% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
See More
Previous Close:
$3.59
Open:
$3.59
24h Volume:
923.64K
Relative Volume:
0.52
Market Cap:
$353.20M
Revenue:
-
Net Income/Loss:
$-166.01M
P/E Ratio:
-1.6363
EPS:
-2.0778
Net Cash Flow:
$-131.32M
1W Performance:
-2.86%
1M Performance:
-5.03%
6M Performance:
-9.09%
1Y Performance:
+17.65%
1-Day Range:
$3.39
$3.66
1-Week Range:
$3.39
$3.73
52-Week Range:
$2.22
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.40 | 372.94M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
Larimar Therapeutics (LRMR) Slides 3.6%: Technical Support Test in FocusTriple Bottom - newsline.com
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Larimar Therapeutics (LRMR) Faces Headwinds as Stock Slides 2.21% to $3.10Momentum Surge Alerts - newsline.com
LRMR Q1 2026 Earnings: EPS Surprise of 43% as Loss Narrows, Stock SlidesPost-Announcement Reaction - newsline.com
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
LRMR Q1 2026 Earnings: EPS Surprise of 43.19% as Net Loss Narrower Than ExpectedProfit Growth Outlook - newsline.com
Larimar Therapeutics (LRMR) Slides 4.3% as Selling Pressure Tests Key SupportFRAMA Signal - newsline.com
Larimar Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Bolsters Operational ProgressRevenue Warning Signal - newsline.com
Larimar Therapeutics (LRMR): Shares Hold Steady Near Support as Consolidation ContinuesBollinger Band - newsline.com
LRMR Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises as Pipeline Progress ContinuesEarnings Forecast Report - thelegaladvocate.com
J.P. Morgan Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $9 - Moomoo
JP Morgan Initiates Coverage of Larimar Therapeutics (LRMR) with Overweight Recommendation - MSN
LRMR Initiates Coverage by JP Morgan -- Rating Set at Overweight - GuruFocus
JPMorgan Initiates Larimar Therapeutics at Overweight With $9 Price Target - marketscreener.com
JPMorgan initiates Larimar Therapeutics stock at Overweight By Investing.com - Investing.com Australia
JPMorgan initiates Larimar Therapeutics stock at Overweight - Investing.com India
80,590,392 Common Stock of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Stock Options of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Restricted Stock Units of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Pre-Funded Warrants of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Larimar Therapeutics (LRMR) Edges Lower as Stock Tests Key Support ZoneComposite Profile - newsline.com
Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study - MSN
[Form 4] Larimar Therapeutics, Inc. Insider Trading Activity - Stock Titan
Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options - Stock Titan
Larimar Therapeutics (LRMR) awards 55,150 stock options to director - Stock Titan
Larimar Therapeutics (LRMR) director receives 55,150 stock options grant - Stock Titan
Larimar Therapeutics (LRMR) director awarded 55,150 stock options at $3.33 strike - Stock Titan
Larimar Therapeutics (LRMR) director gets 55,150 stock options at $3.33 strike - Stock Titan
Larimar Therapeutics stockholders approve board elections and share increase By Investing.com - Investing.com Nigeria
Larimar Therapeutics stockholders approve board elections and share increase - Investing.com
Larimar Shareholders Approve Governance and Capital Structure Changes - TipRanks
Larimar Therapeutics (NASDAQ: LRMR) holders back big authorized share increase - Stock Titan
LRMR Maintained by Wedbush -- Price Target Lowered to $12.00 - GuruFocus
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Larimar Therapeutics Price Target Cut to $12.00/Share From $13.00 by Wedbush - Moomoo
Larimar Therapeutics (LRMR) surges on FDA breakthrough therapy designation - MSN
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Number of shareholders of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Wedbush Adjusts Larimar Therapeutics Price Target to $12 From $13, Maintains Outperform Rating - Moomoo
Larimar Details Q1 Results and Nomlabofusp Regulatory Progress - The Globe and Mail
Exploring US High Growth Tech Stocks This May 2026 - Yahoo Finance
Citizens reiterates Larimar Therapeutics stock rating on FDA progress By Investing.com - Investing.com South Africa
Citizens reiterates Larimar Therapeutics stock rating on FDA progress - Investing.com India
Larimar Therapeutics, Inc. Stock 12‑Month Price Target Cut to $15.88, Implies 287% Upside - TradingView
LARIMAR THERAPEUTICS (LRMR) Advances towards Friedreich's Ataxia Treatment Approval - GuruFocus
Blue Owl (NASDAQ: LRMR) discloses 9.99% position totaling 10.74M shares - Stock Titan
Larimar Therapeutics (LRMR) lifts cash to $200M as FDA grants Breakthrough status - Stock Titan
Larimar Therapeutics 1Q Research and Development Expenses $25.0M >LRMR - Moomoo
Larimar Therapeutics Advances Nomlabofusp for Friedreich’s Ataxia with Rolling BLA Submission and Strong Q1 2026 Financials - Minichart
Larimar Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
LRMR: Nomlabofusp shows strong efficacy and safety in FA, targeting 2027 U.S. launch - TradingView
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Larimar Therapeutics Inc Stock (LRMR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hamilton Thomas Edward | Director |
Feb 27 '26 |
Buy |
5.00 |
100,000 |
500,000 |
664,798 |
| THOMAS FRANK E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
7,000 |
| SHERMAN JEFFREY W | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
5,000 |
| Flynn James E | Director |
Jul 31 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
9,538,945 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):